Nomigrin (Naproxen Sodium, Sumatriptan Succinate)

Naproxen sodium and sumatriptan succinate, the active ingredients in Nomigrin, are an NSAID and a selective 5‑HT1B/1D receptor agonist presented as oral tablets for systemic use. The combination is indicated for the acute treatment of migraine attacks in adult patients.

GNH USA supplies Nomigrin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product is manufactured to EU standards and distributed under strict quality controls to meet global regulatory requirements, ensuring consistent potency and safety for patients.

Nomigrin is used for the acute management of migraine, a neurovascular headache disorder.

- Migraine attack: rapid relief of moderate to severe headache pain. - Migraine with aura: reduction of visual and sensory disturbances associated with the attack. - Acute episodic migraine: alleviation of accompanying nausea, photophobia and phonophobia.

Nomigrin may cause a range of adverse reactions. The most frequently reported events are generally mild and transient.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Dizziness: sensation of light‑headedness. - Tingling or paresthesia: often in the face or extremities. - Chest discomfort: pressure or tightness. - Dry mouth: reduced salivation. - Fatigue: feeling unusually tired.

Serious or Rare Side Effects: - Coronary vasospasm: chest pain with possible cardiac ischemia. - Serotonin syndrome: agitation, hyperthermia, muscle rigidity. - Severe allergic reaction: rash, swelling, anaphylaxis. - Hypertension: sudden increase in blood pressure. - Gastrointestinal bleeding: black stools or vomiting blood. - Stroke or transient ischemic attack: neurological deficits.

Before prescribing Nomigrin, clinicians should evaluate patient‑specific risk factors and monitor for potential complications.

- Cardiovascular assessment: avoid in patients with uncontrolled coronary artery disease. - Drug interaction review: contraindicated with MAO inhibitors and other triptans. - Hepatic function: use caution in moderate to severe liver impairment. - Serotonin syndrome monitoring: be vigilant when combined with serotonergic agents. - Hypersensitivity check: discontinue if signs of allergic reaction appear. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Nomigrin can interact with several medication classes; awareness of major and moderate interactions helps prevent adverse outcomes.

Major Interactions (Avoid): - MAO inhibitors: risk of severe hypertension and serotonin syndrome. - Other triptans or ergot derivatives: additive vasoconstriction. - SSRIs/SNRIs: increased potential for serotonin syndrome. - Potent CYP2C9 inhibitors (e.g., fluconazole): may raise naproxen levels. - Uncontrolled hypertension agents: exacerbate blood pressure spikes.

Moderate Interactions (Monitor Closely):\n- Antihypertensives: possible reduction in blood pressure control. - Anticoagulants/antiplatelet drugs: heightened bleeding risk. - Diuretics: may affect renal clearance of naproxen. - Other NSAIDs: increased gastrointestinal toxicity. - CYP3A4 inducers (e.g., rifampin): may lower sumatriptan exposure.